Addressing cardiometabolic risk during treatment with antipsychotic medications

Current Opinion in Psychiatry

Volumn 21, Issue 6, 2008, Pages 613-618

  Amiel, Jonathan M ^a,e   Mangurian, Christina V ^a   Ganguli, Rohan ^b,c   Newcomer, John W ^d  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e School of Medicine ^*  (United States)

Author keywords

Antipsychotic medications; Metabolic syndrome; Obesity; Schizophrenia

Indexed keywords

GLUCOSE; LIPID; LITHIUM; METFORMIN; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; SIBUTRAMINE; TOPIRAMATE; VALPROIC ACID; ZIPRASIDONE;

BEHAVIOR DISORDER; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DIET; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HEALTH CARE ACCESS; HEART MUSCLE METABOLISM; HUMAN; HYPERGLYCEMIA; LIFESTYLE; LIPID METABOLISM; METABOLIC DISORDER; MORTALITY; OUTCOMES RESEARCH; PRIMARY PREVENTION; PSYCHOSIS; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SIDE EFFECT; SITTING; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; DYSLIPIDEMIAS; HUMANS; HYPERGLYCEMIA; MENTAL DISORDERS; OBESITY; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 56249094545     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e328314b74b     Document Type: Review

References (35)

1. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80:19-32.
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
3. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2008; 3:1-14.
4. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl 1:1-93.
5. Grundy SM, Pasternak R, Greenland P, et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999; 100:1481-1492.
6. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334-1349.
7. American Diabetes Association, the American Psychiatric Association, the American Association of Clinical Endocrinologists, and the North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596-801.
8. Morrato EH, Newcomer JW, Allen RR, Valuck RJ. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of medicaid claims data. J Clin Psychiatry 2008; 69:316-322. Medicaid claims analysis showing poor monitoring of major CVD risk factors in people taking antipsychotic medications.
9. Newcomer JW, Nasrallah HA, Loebel AD. The atypical antipsychotic therapy and metabolic issues national survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004; 24 (5 Suppl 1):S1-S6.
10. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86:15-22.
11. Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 2008; 101:273-286. A subgroup analysis from CATIE showing differential risk of metabolic side effects among antipsychotic medications.
12. L'Italien GJ, Casey DE, Kan HJ, et al. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry 2007; 68:1510-1516. A small study showing higher incidence of metabolic syndrome in people taking olanzapine versus aripiprazole or placebo.
13. Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. Ann Clin Psychiatry 2006; 18:183-194.
14. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophr Res 2008; 99:13-22. A small study suggesting differential risk of metabolic syndrome among antipsychotics decreases over time.
15. Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res 2007; 93:90-98. This study shows first-episode patients are at high risk of developing metabolic side effects on olanzapine.
16. Weiden PJ, Newcomer JW, Loebel AD, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 2008; 33:985-994. An important study showing that switching to ziprasidone is associated with improvement in weight and plasma lipids.
17. Kolotkin RL, Corey-Lisle PK, Crosby RD, et al. Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. Eur Psychiatry 2008 [Epub ahead of print]. This study shows aripirazole therapy is associated with weight loss compared with treatment as usual.
18. Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 2008; 69:1046-1056. A large randomized study demonstrating that switching from olanzapine to aripirazole is associated with weight loss in overweight patients.
19. Khazaal Y, Chatton A, Rusca M, et al. Long-term topiramate treatment of psychotropic drug-induced weight gain: a retrospective chart review. Gen Hosp Psychiatry 2007; 29:446-449. This study shows modest benefit of adjunctive topiramate therapy for weight loss.
20. McElroy SL, Frye MA, Altshuler LL, et al. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. Bipolar Disord 2007; 9:426-434. This study shows modest benefit of topiramate or sibutramine in treating antipsychotic-associated weight gain.
21. Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008; 165:352-358. An important study showing a role for metformin in preventing weight gain for people taking olanzapine.
22. Baptista T, Rangel N, Fernandez V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 2007; 93:99-108. This study suggests that metformin is beneficial in treating olanzapine-induced weight gain.
23. Baptista T, Uzcategui E, Rangel N, et al. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res 2008; 159:250-253. A study finding that adjunctive sibutramine does not confer additional benefit over metformin alone in treating olanzapine-associated weight gain.
24. Faulkner G, Conn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007:CD005148.
25. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
26. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care 1997; 20:537-544.
27. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-1350.
28. Khazaal Y, Fresard E, Rabia S, et al. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr Res 2007; 91:169-177. A study showing cognitive behavioral therapy can reduce binge-eating symptoms in people treated with antipsychotic medication.
29. Pendlebury J, Haddad P, Dursun S. Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results. Hum Psychopharmacol 2005; 20:447-448.
30. Pendlebury J, Bushe CJ, Wildgust HJ, Holt RI. Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatr Scand 2007; 115:286-294. This study shows enduring effects of behavioral therapy for weight loss in people with SPMI.
31. Sharpe JK, Byrne NM, Stedman TJ, Hills AP. Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication. J Am Diet Assoc 2005; 105:612-615.
32. Sharpe JK, Stedman TJ, Byrne NM, Hills AP. Increasing energy expenditure is important to enhance management of antipsychotic-associated weight gain. J Clin Psychiatry 2005; 66:951-952; author reply 952.
33. Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry 2006; 67:1253-1260.
34. Weber M, Wyne K. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophr Res 2006; 83:95-101.
35. Ganguli R. Behavioral therapy for weight loss in patients with schizophrenia. J Clin Psychiatry 2007; 68 Suppl 4:19-25. An important study finding that behavioral therapy can treat antipsychotic-induced weight loss.